DOMESTIC SUBCUTANEOUS SELF-INJECTION OF BORTEZOMIB IN MULTIPLE MYELOMA
(Abstract release date: 05/19/16)
EHA Library. Cerchione C. 06/09/16; 134900; PB2000
Dr. Claudio Cerchione
Contributions
Contributions
Abstract
Abstract: PB2000
Type: Publication Only
Background
Bortezomib-based therapies are suggested as standards of care in management of patients with newly diagnosed and relapsed multiple myeloma. The recommended dose and schedule of Bortezomib is 1.3 mg/mq administred on days 1, 4, 8, and 11 of 21-day cycles, a regimen active and well tolerated. Subcutaneous administration of bortezomib could be a good option for patients, particularly those with poor venous access.It’s known that home intravenous administration of bortezomib is feasible to adequately informed patients, because we have recently demonstrated that a solution of bortezomib powder in normal saline stored at 4°C remains stable for nearly one month.
Aims
Since 2009, in our unit all patients requiring bortezomib for the treatment of multiple myeloma perform intravenous injection of the drug at home, after having been supplied with the exact dose in saline solution, in ready-to-use plastic syringes, appropriately preparedunder hood in sterile conditions. This procedure reduces the time spent by patients in hospital, improving convenience for patients and physicians. However, in some patients venous access may be difficult or sometimes unfeasible. As the drug is not histotoxic, subcutaneous administration is feasible, and this possibility is particularly attractive in domestic settings.
Methods
Safety and efficacy of subcutaneous injections of bortezomib at the same dose as i.v. administrations (1mg/sm, days 1, 4, 8, 11), but dissolved in smaller saline volume (max. 1ml), in association with oral dexamethasone 20mg/dd. 1-2,4-5, 8-9, 11-12, was verified in 108 patients affected by multiple myeloma, with poor venous access.In particular, the efficacy, evaluated as reduction of the monoclonal component during the i.v. period vs. the s.c. period was performed in a subgroup of 12 patients.
Results
Results indicated an equivalence between the two administration modalities, according to other larger controlled studies.Based on these reports, 108 patients, requiring Bortezomib as part of anti Myeloma regimens, have been systematically treated by subcutaneous injections, performed at home. No significant side effects have been reported so far and quality of life is particularly improved.In particular, in 37 of them we have evaluated an equivalence between the subcutaneous and intravenous administration, according to other controlled studies.
Conclusion
The possibility to perform an antineoplastic regimen at home is particularly well accepted by all patients affected by multiple myeloma, with an achievement of a very good quality of life.
Session topic: E-poster
Keyword(s): Bortezomib, Myeloma
Type: Publication Only
Background
Bortezomib-based therapies are suggested as standards of care in management of patients with newly diagnosed and relapsed multiple myeloma. The recommended dose and schedule of Bortezomib is 1.3 mg/mq administred on days 1, 4, 8, and 11 of 21-day cycles, a regimen active and well tolerated. Subcutaneous administration of bortezomib could be a good option for patients, particularly those with poor venous access.It’s known that home intravenous administration of bortezomib is feasible to adequately informed patients, because we have recently demonstrated that a solution of bortezomib powder in normal saline stored at 4°C remains stable for nearly one month.
Aims
Since 2009, in our unit all patients requiring bortezomib for the treatment of multiple myeloma perform intravenous injection of the drug at home, after having been supplied with the exact dose in saline solution, in ready-to-use plastic syringes, appropriately preparedunder hood in sterile conditions. This procedure reduces the time spent by patients in hospital, improving convenience for patients and physicians. However, in some patients venous access may be difficult or sometimes unfeasible. As the drug is not histotoxic, subcutaneous administration is feasible, and this possibility is particularly attractive in domestic settings.
Methods
Safety and efficacy of subcutaneous injections of bortezomib at the same dose as i.v. administrations (1mg/sm, days 1, 4, 8, 11), but dissolved in smaller saline volume (max. 1ml), in association with oral dexamethasone 20mg/dd. 1-2,4-5, 8-9, 11-12, was verified in 108 patients affected by multiple myeloma, with poor venous access.In particular, the efficacy, evaluated as reduction of the monoclonal component during the i.v. period vs. the s.c. period was performed in a subgroup of 12 patients.
Results
Results indicated an equivalence between the two administration modalities, according to other larger controlled studies.Based on these reports, 108 patients, requiring Bortezomib as part of anti Myeloma regimens, have been systematically treated by subcutaneous injections, performed at home. No significant side effects have been reported so far and quality of life is particularly improved.In particular, in 37 of them we have evaluated an equivalence between the subcutaneous and intravenous administration, according to other controlled studies.
Conclusion
The possibility to perform an antineoplastic regimen at home is particularly well accepted by all patients affected by multiple myeloma, with an achievement of a very good quality of life.
Session topic: E-poster
Keyword(s): Bortezomib, Myeloma
Abstract: PB2000
Type: Publication Only
Background
Bortezomib-based therapies are suggested as standards of care in management of patients with newly diagnosed and relapsed multiple myeloma. The recommended dose and schedule of Bortezomib is 1.3 mg/mq administred on days 1, 4, 8, and 11 of 21-day cycles, a regimen active and well tolerated. Subcutaneous administration of bortezomib could be a good option for patients, particularly those with poor venous access.It’s known that home intravenous administration of bortezomib is feasible to adequately informed patients, because we have recently demonstrated that a solution of bortezomib powder in normal saline stored at 4°C remains stable for nearly one month.
Aims
Since 2009, in our unit all patients requiring bortezomib for the treatment of multiple myeloma perform intravenous injection of the drug at home, after having been supplied with the exact dose in saline solution, in ready-to-use plastic syringes, appropriately preparedunder hood in sterile conditions. This procedure reduces the time spent by patients in hospital, improving convenience for patients and physicians. However, in some patients venous access may be difficult or sometimes unfeasible. As the drug is not histotoxic, subcutaneous administration is feasible, and this possibility is particularly attractive in domestic settings.
Methods
Safety and efficacy of subcutaneous injections of bortezomib at the same dose as i.v. administrations (1mg/sm, days 1, 4, 8, 11), but dissolved in smaller saline volume (max. 1ml), in association with oral dexamethasone 20mg/dd. 1-2,4-5, 8-9, 11-12, was verified in 108 patients affected by multiple myeloma, with poor venous access.In particular, the efficacy, evaluated as reduction of the monoclonal component during the i.v. period vs. the s.c. period was performed in a subgroup of 12 patients.
Results
Results indicated an equivalence between the two administration modalities, according to other larger controlled studies.Based on these reports, 108 patients, requiring Bortezomib as part of anti Myeloma regimens, have been systematically treated by subcutaneous injections, performed at home. No significant side effects have been reported so far and quality of life is particularly improved.In particular, in 37 of them we have evaluated an equivalence between the subcutaneous and intravenous administration, according to other controlled studies.
Conclusion
The possibility to perform an antineoplastic regimen at home is particularly well accepted by all patients affected by multiple myeloma, with an achievement of a very good quality of life.
Session topic: E-poster
Keyword(s): Bortezomib, Myeloma
Type: Publication Only
Background
Bortezomib-based therapies are suggested as standards of care in management of patients with newly diagnosed and relapsed multiple myeloma. The recommended dose and schedule of Bortezomib is 1.3 mg/mq administred on days 1, 4, 8, and 11 of 21-day cycles, a regimen active and well tolerated. Subcutaneous administration of bortezomib could be a good option for patients, particularly those with poor venous access.It’s known that home intravenous administration of bortezomib is feasible to adequately informed patients, because we have recently demonstrated that a solution of bortezomib powder in normal saline stored at 4°C remains stable for nearly one month.
Aims
Since 2009, in our unit all patients requiring bortezomib for the treatment of multiple myeloma perform intravenous injection of the drug at home, after having been supplied with the exact dose in saline solution, in ready-to-use plastic syringes, appropriately preparedunder hood in sterile conditions. This procedure reduces the time spent by patients in hospital, improving convenience for patients and physicians. However, in some patients venous access may be difficult or sometimes unfeasible. As the drug is not histotoxic, subcutaneous administration is feasible, and this possibility is particularly attractive in domestic settings.
Methods
Safety and efficacy of subcutaneous injections of bortezomib at the same dose as i.v. administrations (1mg/sm, days 1, 4, 8, 11), but dissolved in smaller saline volume (max. 1ml), in association with oral dexamethasone 20mg/dd. 1-2,4-5, 8-9, 11-12, was verified in 108 patients affected by multiple myeloma, with poor venous access.In particular, the efficacy, evaluated as reduction of the monoclonal component during the i.v. period vs. the s.c. period was performed in a subgroup of 12 patients.
Results
Results indicated an equivalence between the two administration modalities, according to other larger controlled studies.Based on these reports, 108 patients, requiring Bortezomib as part of anti Myeloma regimens, have been systematically treated by subcutaneous injections, performed at home. No significant side effects have been reported so far and quality of life is particularly improved.In particular, in 37 of them we have evaluated an equivalence between the subcutaneous and intravenous administration, according to other controlled studies.
Conclusion
The possibility to perform an antineoplastic regimen at home is particularly well accepted by all patients affected by multiple myeloma, with an achievement of a very good quality of life.
Session topic: E-poster
Keyword(s): Bortezomib, Myeloma
{{ help_message }}
{{filter}}